Helical TomoTherapy has unique challenges in handling intrafractional motion compared to a conventional LINAC. In this study, we analyzed the impact of intrafractional motion on cumulative dosimetry using actual patient motion data from clinically treated patients and investigated real time jaw and multileaf collimator (MLC) compensation approaches to minimize the motion-induced dose discrepancy in clinically acceptable TomoTherapy lung SBRT treatments. Intrafractional motion traces from eight fiducial tracking CyberKnife lung tumor treatment cases were used in this study. These cases were re-planned on TomoTherapy for SBRT, with 18 Gy×3 fractions to a planning target volume (PTV) defined on the breath-hold CT without ITV expansion. Each case was planned with four different jaw settings: 1 cm static, 2.5 cm static, 2.5 cm dynamic and 5 cm dynamic. In-house 4D dose accumulation software was used to compute the dose distributions with tumor motion and then compensate for that motion by modifying the original jaw and MLC positions to track the trajectory of the tumor. The impact of motion and effectiveness of compensation on the PTV coverage depends on the motion type and plan settings. On average, the PTV V 100% (the percent volume of the PTV receiving the prescription dose) accumulated from three fractions changed from 96.6% (motionfree) to 83.1% (motion-included), 97.5% to 93.0%, 97.7% to 92.1%, and 98.1% to 93.7% for the 1 cm static jaw, 2.5 cm static jaw, 2.5 cm dynamic jaw and 5 cm dynamic jaw setting, respectively. When the jaw and MLC compensation algorithm was engaged, the PTV V 100% was restored back to 92.2%, 95.9%, 96.6% and 96.4%, for the four jaw settings mentioned above respectively. TomoTherapy lung tumor SBRT treatments using a field width of 2.5 cm or larger are less sensitive to motion than treatments using a 1 cm field width. For 1 cm field width plans, PTV coverage can be greatly compromised, even over three fractions. Once the motion pattern is known, the jaw and MLC compensation algorithm can largely minimize the loss of PTV coverage induced by the motion.
Introduction
Helical TomoTherapy ® (Accuray Inc., Sunnyvale, CA) is a method of radiation therapy that utilizes a helical delivery of dose to a patient in a slice-by-slice fashion similar to that of a helical computed tomography (CT) scanner [1, 2] . The gantry ring will continuously rotate as the patient continuously translates through the bore. A compact 6 MV S-band linear accelerator is attached to the gantry which delivers a fan beam that is collimated by longitudinal jaws and a binary multileaf collimator [1, 3] . The fan beam can laterally extend 40 cm at isocenter and has a maximum longitudinal field size of 5 cm at isocenter. In the lateral direction, a binary 64-leaf collimator is used with a leaf width of 0.625 cm projected to isocenter. There are 51 projections (gantry positions) per gantry rotation that are used to define the beam delivery by creating leaf patterns at each projection. Traditionally, static longitudinal field sizes of 1.0 cm, 2.5 cm, and 5.0 cm are used for the jaw settings. Dynamic jaws (TomoEDGE Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.
the motion of jaws in the beginning and end of treatment to conform to the target [4] . This techniques allows for full field size delivery specified by the plan within the target to speed up treatment delivery, while dynamically closing the jaws to 1 cm at the superiorinferior borders of the target for sharper dose fall off [5] .
During radiation therapy delivery, treatment targets (i.e. tumors) are often not stationary. Motion induced artifacts include dose blurring and the interplay effect between target motion and beam modulation by the couch, gantry, jaws and MLC [5] [6] [7] [8] [9] [10] [11] . The interplay between intensity modulated deliveries and tumor motion is particularly concerning because many segments are smaller than the target [9, 12] . Papers investigating the interplay effect quote possibly large dosimetric differences of up to 20%-30% for a single fraction, but report that differences largely wash out with many fractions [5, 9, 13] . A TomoTherapy simulation study by Kissick et al showed that the interplay effect was likely small in the presence of a sinusoidal motion, however even a small amount of randomness in motion trace can change the fluence intensity profiles dramatically [6] . Therefore, in the context of lung stereotactic body radiotherapy (SBRT) treatment, which uses few fractions, high dose per fraction and where the subject has realistic irregular respiratory cycles, the interplay effect is still a concern.
The clinical impact of intrafractional motion on TomoTherapy has been reported for prostate treatments planned with a 2.5 cm fixed jaw plan and conventional fractionation [14, 15] . In the lung, small dose blurring was observed for the delivery of TomoTherapy 1 cm fixed jaw plan in a phantom study, however the motion used was relatively small (1 cm) and regular [7] . There are no known publications of effects from realistic intrafractional motion for the case of lung stereotactic body radiation therapy (SBRT) on TomoTherapy systems using the relatively new dynamic jaws feature.
On non-TomoTherapy systems, several intrafractional motion management techniques are used clinically or have been studied in pre-clinical settings. On conventional linacs, techniques including gating, breath hold and forced shallow-breathing with the use of abdomen compression have been routinely used in the clinic [11, [16] [17] [18] . There were a series of publications on integrating MLC target tracking with the feedback from an electromagnetic position tracking system (Calypso 4D Localization System) [8] [9] [10] [11] . Although 1-2 mm accuracy was achieved in the experimental system, there is no clinical implementation treating patients yet. The CyberKnife ® Treatment Delivery System (Accuray Inc., Sunnyvale, CA) is a clinically available radiation treatment device that adjusts the delivery to the motion of the tumor with the use of a mobile robotic arm. It can track the skull, spine and fiducial markers within the patient and adjust the linac head to deliver the radiation to the target. When treating lung tumors with CyberKnife, a motion correlation model between superficial landmarks and the internal target or fiducials is built-the Synchrony ® Respiratory Tracking System-and used to dynamically guide the gantry head to follow the target continuously [12] .
In the case of TomoTherapy, there are fewer viable active intrafractional motion management techniques used in the clinic. On the research side, software motion compensation for TomoTherapy includes MotionAdaptive Delivery (MAD) and Motion-Adaptive Optimization (MAO) that have been previously investigated [13, 14, 19] . MAD is a software approach that rearranges planning projections and leaf patterns to best match the motion of the target. This method of motion compensation, however, struggles with erratic non-periodic motion [19] . Unlike MAD, MAO performs single projection optimization based on the delivered dose accumulation, motion detection and future dose estimation but is limited by computational speed [14] . Zhou et al, include pre-and-intrafractional megavoltage compute tomography (MVCT) images to compensate for any changes during the first portion of a lung SBRT treatment [20] . They found shifts were needed from the intrafractional MVCT but did not address consistent intrafractional tumor motion during the treatment. To handle real time intrafractional motion in TomoTherapy, groups have looked into gating by delivering radiation at certain breathing amplitude positions at specified couch positions as the patient moves through the bore until all pulses for each angle have been delivered [21] . There are also two methods of breath hold that have been investigated: the first method has the gantry move during the rest period between breath-holds and will beam-on when patient is in the breath hold position [16] . The second method scales back the dose so that the whole longitudinal extent can be covered in one breath hold and repeated until the prescription is reached [17] .
Recently Schnarr et al [18] described the implementation of sequential monoscopic imaging, and the adaptation of the motion correlation model from CyberKnife to an experimental TomoTherapy system. Observed motion was compensated through real-time adjustment of the jaws and the MLC leaf patterns, which continually repoint the treatment beam at the moving target. They performed phantom studies on their experimental TomoTherapy machine and showed that respiratory motion (regular and 15 mm peak to peak) of a cylindrical target can be compensated in a 1 cm fixed jaw plan. The phantom plan used in their study, however, did not have realistic patient contours nor was the plan optimization guided by clinical objectives.
In the present study, we aim to investigate the realistic consequences of lung tumor motion and the effectiveness of compensation by using real patient motion, clinical plans optimized on actual patient anatomy and four typical jaw settings used in clinical treatments. Unlike previous research mentioned above, the plans used in our evaluation are clinically acceptable treatment plans in the SBRT lung setting following in-house clinical guidelines that could be used for treatment. This approach is a further and much more clinical relevant investigation into the dose compensation and tracking algorithm's ability to handle more complex and realistic situations in the patient treatment. As TomoTherapy works towards providing a clinically feasible and efficient method for real-time tumor tracking [18] , the synchronization of intensity modulated radiation therapy (IMRT) with real-time compensation as a method of motion management needs to be further investigated. We used inhouse dose calculation software [22] to explore how dose distributions are affected by target motion in TomoTherapy by including the trajectory of tumor motion. More importantly, it also provides us the ability to compensate for motion by adjusting static/ dynamic jaw and MLC leaf patterns in a way that is similar to something that Accuray is developing. Thus it allows us to study this anticipated motion tracking and compensation technique when applied to realistic clinical plans and target motions, and determine whether such a system could provide a competitive method for treating tumors in the lung SBRT setting.
Methods and materials

Treatment plans and motion traces
Eight lung cancer patients with a variety of tumor motions were included in this study. All patients received two to four fiducial implants and were originally treated on CyberKnife coupled with fiducial tracking. The patients were scanned with two sets of CT scanning protocols: a high-resolution (1 mm) breath hold CT, used as the planning CT, and a normal resolution (3 mm) 4D CT. All phases of 4D CTs and planning CT were registered on the fiducials, and then the residual displacement of the tumor among these images was used for margin estimation. The gross tumor volume (GTV) was contoured on the breath hold CT then expanded to the planning target volume (PTV) according to the margin found before.
Treatments were retrospectively planned for TomoTherapy on the breath hold CT using helical delivery with 18 Gy×3 fractions (54 Gy in total) to an approximate 80% isodose line to simulate the dosimetry of a CyberKnife treatment. The PTV was optimized to have at least 95% of the volume to be covered by 100% of prescription dose according to institutional (UNC) policy and organs at risk (OARs) were spared per AAPM TG 101 recommendations [23] . Four dose tuning structures were contoured to force high doses close to the center of the GTV and quick dose fall off outside the PTV [24] . Four clinical plans were generated for each patient with these commonly used jaw settings: 1 cm fixed, 2.5 cm fixed, 2.5 cm dynamic and 5 cm dynamic. The pitch was 0.14, modulation factors were between 1.4 to 1.8, gantry rotation periods of 35 s to 50 s, and treatment times from about 10 min to 30 min.
The motion of the fiducials was retrieved from the Synchrony tracking model and motion log of actual CyberKnife treatments. The inter-fiducial distance was verified by the system during the image registration process before the beam was turned on for CyberKnife treatment. The selected patients in this study were all treated successfully on CyberKnife with no obvious migration of fiducials. Due to this, the fiducials serve as a good substitute of the tumor itself when evaluating tumor motion. In the rest of this study, the tumor motion and fiducial motion are used interchangeably. For each patient, the tumor motion was recorded over 3 separate deliveries, and each recorded motion was unique and generally an hour long. Intrafractional motion management is needed more for the patients with large motion. In our previous study, we demonstrated the motion has more of an effect along the longitudinal direction on the helical TomoTherapy delivery compared to the other two directions [25] . To demonstrate the effectiveness of the proposed motion compensation method, we purposely chose 3 patients with average amplitude of peak-to-peak motion (10-20 mm in longitudinal direction) and 5 patients with very large motion (>25 mm). Table 1 summarizes the tumor location, size, longitudinal dimension and maximum perk-to-peak motion amplitude along the longitudinal direction. The dominant frequency is in the range of 0.2 Hz to 0.33 Hz. A subsection of tumor motion data, the same length as the TomoTherapy plan delivery time (30 min), was selected from the middle of each recording for the dose study. The rigid motion traces of the fiducials (tumor) in all three directions were incorporated into our dose calculation software to study the motion impact and compensation effect.
Dose calculation with motion
The dose calculation software used in this research was implemented as a fast GPU calculation algorithm that accurately predicts the effects of motion in TomoTherapy dose delivery [22] . It takes target motion as an input time series and simulates a rigid translational motion of the target by virtually adjusting the couch to move in any direction at any time point thus replicating the motion of the tumor, then calculating the dose deposited within that time point. The dose calculation is performed at three angles per projection and there are 51 projections per rotation resulting in a dose calculation resolution of one calculation about every 0.1-0.3 s for our tested clinical plans. Jaw compensation is implemented by shifting the jaw positions such that the center of the treatment beam moves with the target in the longitudinal direction while maintaining jaw width as specified in the original plan. In this simulation, the maximum shift of the field edge from the original centerline is limited to 3 cm, corresponding to the current mechanical limits of the TomoTherapy jaws. Similarly, MLC compensation is achieved by adjusting the opening of certain leaves which best match the new location of the target in the beams eye view transverse direction.
Workflow and data analysis
The overall suggested clinical workflow is demonstrated in figure 1 . A more detailed description of the image guided motion modelling and a dosimetric validation of the dose calculation software can be found in the previous phantom study papers by Schnarr et al [18] and Chao et al [22] , respectively. This paper focuses on the other aspect of the project: the motion impact on clinical plans and dosimetric effectiveness of compensation.
In this study, we first calculated the delivered dose in each of three fractions using the three unique motion traces for each patient. The treatment anatomy was assumed to have not changed from the planning CT and no tissue deformation was considered. In order to compensate for the motion, the jaw and MLC were adjusted to track the tumor motion. Motion compensated dose for each fraction was then re-calculated and the total dose from all three fractions was accumulated. The percent volume of the PTV receiving the prescription dose (PTV V 100% ) was tracked for target coverage assessment. Dosimetry for lung organs at risk (OAR) was not analyzed because the motion of these organs may not be related to the recorded motions of the fiducials implanted in the tumor. The motion-free original plan was used as the reference dosimetry for comparison. Wilcoxon signed rank test (Matlab, Mathworks, Natick, MA) was used as statistical testing tool. figure 2(b) . In general, the PTV is covered by a relatively conformal dose in all of the plans except for the 2.5 cm fixed jaw plan which has a less sharp dose fall-off on the superior and inferior border of the PTV compared to the other three plans due to the bigger jaw size used when treating that portion of the PTV. Most normal tissue sparing is similar, so DVH curves for these OARs are not displayed. The special issue with this treatment plan is that the chest wall abuts the PTV, which made sparing it very challenging. Our institutional policy allows minor violation of the chest wall constraint in order to strive for sufficient dose on the tumor. For the dosimetry of the chest wall, a 1 cm fixed jaw plan outperformed the others, followed by the 2.5 cm dynamic jaw plan. Table 2 shows the statistics of dosimetric endpoints of critical structures averaged for all eight patients. As in the sample patient's plans, the 1 cm fixed jaw plans achieve superior dosimetric quality in terms of chest wall sparing and less lung dose, but similar quality for other important structures such as the spinal cord and heart. The dosimetry of the 2.5 cm dynamic jaw plans was not as good as in the 1 cm plans, but generally outperformed the 5 cm dynamic jaw or 2.5 cm fixed jaw settings studied. The 2.5 cm dynamic jaw plans could be delivered in half the time as compared to the 1 cm plans. The 5 cm dynamic jaw plans generally had the least favorable dosimetry, but could be delivered in the least amount of time.
Results
3.1. Dosimetry of clinical plans of four jaw settings Before showing motion effects and compensation, we present the quality of the original clinical plans with no motion (motion-free plan). A sample patient, one of the 8 cases studied, will help illustrate plan quality achieved with different field width settings. Isodoses for the sample patient, planned with a 1 cm fixed jaw are shown in figure 2(a), and dose-volume histogram (DVH) curves for plans with 1 cm fixed jaw, 2.5 cm fixed jaw, 2.5 cm dynamic jaw and 5 cm dynamic jaw are shown in
Impact of intrafractional motion
A 100 s selection of a respiratory trace (position versus time) of one sample patient is illustrated in figure 3(a) . Please note that our treatment plans have treatment times longer than 100 s and we are showing the first 100 s to make the waveform in the sample more visible. With such a respiration trace, the dose difference between the motion free plan and the motion impacted plan in a single fraction using a 1 cm fixed jaw is calculated to be up to 4.5 Gy (see profile in figure 3(b) ), which is 25% of prescribed fractional dose. In this instance, the accumulated dose from all three fractions did not average out. In the accumulated results for this sample plan, the PTV is still under-dosed, and achieves only 80.3% PTV V 100% .
The change of PTV V 100% after accumulating dose from three fractions for all 4 jaw setting variations and for all 8 patients is presented in figure 3(c) . The PTV V 100% drops from the motion free plan to the motion impacted plan: the 1 cm fixed jaw plans suffered the most with an average deficit of 13.5% to the PTV V 100% and 5 cm dynamic plans being the least affected with a deficit of 4.4%. Using the Wilcoxon signed rank test on the accumulated dosimetry of all plans, we found the significant change of PTV coverage (p<0.01) for all motion impacted plans compared with the original plans.
Effect of motion compensation by tracking
Both jaw and MLC compensation were utilized simultaneously to recover the dosimetry impacted by the motion during treatment. For the sample motion reported in figure 3 and the 1 cm fixed jaw plan, the superior and inferior jaws were adjusted to follow the motion of the tumor along the longitudinal direction ( figure 4(a) ) over the course of approximately 1300 s (only 100 s shown for clarity). Another sample jaw trace using a 2.5 cm dynamic jaw in the scenario of motion tracking was demonstrated in figure 4 (b) (all 660 s shown). It indicates that a tight 1 cm opening was used on both ends of the PTV but returned to normal field width (2.5 cm) in the middle of the PTV. The MLC leaf pattern was shifted to adjacent leaves so that the open aperture was aimed at the PTV at every time point during delivery. The TomoTherapy planning sinogram (MLC leaf pattern over time) of the original plan, motion corrected plan and the difference are shown in figure 4(c) .
The ability of the jaw and MLC to compensate for motion, along with the uncompensated motion impact of a sample patient case is shown in figures 5(a)-(d) , for the 1 cm fixed jaw, 2.5 cm fixed jaw, 2.5 cm dynamic jaw and 5 cm dynamic jaw plans, respectively. The dose difference shown on the CT (motion compensated-original) and DVHs both come from accumulated dosimetry of all three fractions for this sample patient. The 1 cm fixed jaw plan showed more motion sensitivity. However, the compensation was capable of recovering the lost PTV V 100% coverage for this case: the PTV V 100% without motion is 97.7%, it decreased to 80.3% with motion, and recovered to 95.4% with motion compensation ( figure 5(a) ). For this sample patient, the plans with larger jaws settings, 2.5 cm or larger, were less impacted by the motion and had better dosimetric recovery. With jaw and MLC tracking, PTV V 100% coverage was restored back to 97.5%, 98.4%, and 98.9% for 2.5 cm fixed jaw, 2.5 cm dynamic jaw and 5 cm dynamic jaw plan, respectively (figures 5(b)-(d)). Please note the 2.5 cm dynamic and 5 cm dynamic plans both employed a 1 cm field width at the superior/inferior border of the PTV, therefore the deterioration of dosimetry at the superior/inferior ends of these two plans behaves similarly to the 1 cm fixed jaw plan. However, when radiation is directed at the middle portion of the PTV, the plans with dynamic jaw settings restore the field width back to the nominal value of the plan (2.5 cm or 5 cm). This made the overall dosimetry of dynamic jaw plans, as shown in the DVH curves, less severely affected by the motion and better recovered by jaw/MLC tracking as compared to 1 cm fixed jaw plan. The benefit of motion compensation is further proved by the comparisons of PTV coverage between the original and motion compensated plans across all plans and all 8 patients (figure 6). PTV V 100% on plans with the jaw at 2.5 cm or larger can be compensated back to close to 95%, while the compensation on 1 cm jaw plan restored the PTV V 100% to >87%. The mean dosimetry of all 8 patients given in table 3 revealed that jaw and MLC tracking recovered the average PTV V 100% back to 92.2%, 95.9%, 96.6% and 96.4% for 1 cm fixed jaw, 2.5 cm fixed jaw, 2.5 cm dynamic jaw and 5 cm dynamic jaw, respectively. With the Wilcoxon signed rank test, we found the significant improvements of PTV V 100% (p<0.01) for three motion compensated plans (1 cm fixed jaw, 2.5 cm fixed jaw and 2.5 cm dynamic jaw) while 5 cm dynamic jaw plan is improved less significantly (p=0.07).
Discussion
In a hypofractionation setting like SBRT, the effect of the motion of a lung tumor can often be substantial and not easily mitigated with fewer fractions. Therefore, in most TomoTherapy planning situations an internal target volume (ITV) will be determined for planning, which encompasses the maximum extent of tumor motion by aligning phase CTs on the stationary landmarks, like the spine. This helps mitigate some concerns of target under-dose. However, the use of such an ITV will cause higher doses to nearby OARs, as the treatment volume will be larger compared to directly using a GTV to PTV expansion on breath-hold CT. With the addition of real time motion tracking and compensation to TomoTherapy, we can instead use the same contours as in CyberKnife treatments, which directly employ GTV to PTV expansions. By using real patient motion data and clinical plans, we have demonstrated that the proposed motion tracking method can largely recover PTV coverage similar to that in the original motion-free plans when using these smaller margins. The 1 cm field-width plans had the best planned (no-motion) dosimetry, but they also suffered the most from motion: with motion, the PTV V 100% decreased by 13.5% on average (from 96.6% to 83.1%), and with motion compensation it only partially recovered to 92.2% for the PTV V 100% coverage on average. The other 3 field-width settings were less affected by motion, where the PTV V 100% decreased by 5.6% or less, and was largely recovered using motion compensation: Jaw and MLC tracking recovered the PTV V 100% back to 95% or larger for plans with 2.5 cm jaw or larger. Another weakness of 1 cm jaw plans is treatment time, which is about 2-3 times longer than that of the other plans with larger jaw settings. So, despite the marginally better dosimetry for some OARs, the 1 cm jaw plan is a less preferred option for treating tumors exhibiting large motion. As a balanced solution, a field width of 2.5 cm or larger is preferred to minimize the impact of motion and to have acceptable motion compensation and treatment efficiency.
Previous published studies of this jaw and MLC compensation technique for lung motion on TomoTherapy presented results based on simplified target motions and non-clinical treatment plans [18, 22] . These studies acquired film measurements to validate their simulation results, where both measurements and simulations showed the motion corrected dose matched well with the planned dose (<2% difference) when the jaw and MLC tracking were engaged. In this current study, realistic motion was recorded from 24 patient treatment factions and covered a much wider variety of motion patterns. Some of the motion patterns have a larger amplitude along with more irregularity such as sudden anomalies in target motion compared to the relatively regular motion traces used in the previous published work [18, 22] . In addition, the treatment plans included in this study also use patient anatomy and follow a clinical protocol. The dose falloff becomes more asymmetrical and realistic in order to spare the surrounding critical structures such as the chest wall and spinal cord. Overall the clinical plans used in this study are much more complicated than the previously studied non-clinical plans. Taking into account these realistic scenarios, this study shows that the motion effects could be mostly compensated on real clinical cases. It also demonstrates where this technique will struggle and which situations it can be beneficial to end-users within his or her clinic. In future work, we intend to further validate the motion compensation of these patient plans in a treatment delivery study.
For comparison with a prior patient study, Langen et al reported about a 0.3% drop of PTV D 95% (minimum dose received by the hottest 95% of the volume) when delivered dosimetry of three fractions was accumulated for the prostate case using 2.5 cm fixed jaw plan and Calypso tracking data [15] . We also use a 2.5 cm fixed jaw setting; however, our lung study shows PTV coverage as defined by the V 100% can be impaired as much as 4.5%. When a target is underdosed, V 100% and D 95% index show similar trend of deficiency, but may scale differently dependent on the slope of the DVH curve. Secondly, this may be caused by the larger motion for the lung cases in our study, especially along the longitudinal direction where the missed dose cannot be easily remedied due to the narrow field width and moving couch during treatment.
One limitation of this work is that the dosimetry of the normal tissue in the motion impacted and motion compensated plans was not reported because of the difficulty associating the tumor motion pattern with that of surrounding organs. With this motion management technique, fluence is moved to follow the motion of the tumor, which implies that normal tissue near the tumor should be spared better compared to no intervention at all. In a future study, it should be possible for some disease sites to estimate the dose of an OAR that is static (such as a nearby bone) or that has a known motion. For example, in the prostate case the high doses region of the rectum and bladder often exists in the overlap area with the prostate, which moves together with the prostate. In a separate study, Price et al showed the high dose of the bladder and rectum can be better limited in a motion corrected plan [25] .
Another limitation of this work is the assumption that the patient anatomy remains the same, when accumulating dose over the three fractions. It has been reported that the lung tumor size normally changes very little among 3-5 fractions of SBRT [26] . However, for individual clinical cases the daily verification CT could be checked to verify this.
A technical concern of tumor tracking is the accuracy of estimating real time tumor position. This concern has been mostly addressed by adapting a tracking technique from the established CyberKnife Synchrony technology, and by experimental study of this technique as adapted to TomoTherapy [18] . The experimental TomoTherapy machine has a mounted kV imager that acquires sequential monoscopic imaging to capture anatomical movement of the target of interest. These internal markers such as fiducials can be correlated with an external breathing trace captured by an optical camera at the foot of the TomoTherapy couch for lung targets. A model is then built that predicts the location of the fiducials based on the prior kV images and breathing motion trace to adjust the delivery of the beam throughout the course of treatment. The model will be checked continuously against the most recent kV image. The model will be rebuilt if the model prediction deviates from the current measurement over a threshold. This method in fact has many similarities with the established CyberKnife synchrony tracking method, which has been used to treat patients for many years [27] . The study of the prototype TomoTherapy intrafractional management was reported in details by Schnar's et al [18] . This TomoTherapy version of Synchrony, with motion correction enabled, produced film measurements showing the dose differences in a moving target were less than 2%. The robustness of the position modeling remains to be evaluated for special cases like a sudden pattern change or extreme excursion over the jaw shift hardware limit. The exact latency of motion compensation delivery achievable in a production implementation remains to be determined, although it is estimated to be about 70 msecs and should not have a noticeable effect in correcting for respiratory motion.
Conclusion
Our study showed that using a larger treatment beam (2.5 or 5 cm) minimizes the dosimetric impact of intrafractional motion in TomoTherapy helically delivered lung tumor SBRT treatments. In addition, we showed that the ability to adjust the jaws and MLC during treatment to dynamically compensate for target motion largely eliminated the dosimetric impact of measured intrafractional motion gathered from actual patient motion traces, regardless of which treatment beam was selected during planning.
